DYNE THERAPEUTICS INC (DYN)

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 136 full-time employees. The company went IPO on 2020-09-17. The firm is focused on advancing therapeutics for patients with genetically driven diseases. The company is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that it has designed to target the genetic basis of the disease. Using its FORCE platform, the Company is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. The firm also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Company Info

DYNE THERAPEUTICS INC

1560 Trapelo Road

Waltham MASSACHUSETTS 02451

P: 17817868230

CEO: Joshua Brumm

Employees: 136

Website: https://www.dyne-tx.com/